Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, BV Stefánsson, N Jongs… - The lancet Diabetes & …, 2021 - thelancet.com
Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …
被引用次数：368 相关文章

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, B Stefansson, N Jongs… - Lancet Diabetes & …, 2021 - discovery.ucl.ac.uk
Background: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, BV Stefánsson, N Jongs, GM Chertow… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, BV Stefánsson, N Jongs… - The lancet. Diabetes …, 2021 - europepmc.org
Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, BV Stefánsson, N Jongs… - Lancet Diabetes & …, 2021 - research.rug.nl
BACKGROUND: Dapagliflozin reduces the risk of kidney failure and heart failure in patients
with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

ikm.ku.dk
Background: Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis …

DC Wheeler, BV Stefánsson, N Jongs… - The Lancet Diabetes & …, 2021 - Elsevier
Background Dapagliflozin reduces the risk of kidney failure and heart failure in patients with
chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney …

[引用][C] Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified …

DC Wheeler, BV Stefánsson, N Jongs… - The Lancet Diabetes & …, 2021 - cir.nii.ac.jp
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with
diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD …